{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:08:09Z","timestamp":1762884489136,"version":"3.45.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-05099-z","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:57:24Z","timestamp":1762775844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shugan Xiaozhi Decoction attenuates nonalcoholic steatohepatitis by modulating oxidative stress and AMPK pathway"],"prefix":"10.1186","volume":"25","author":[{"given":"Rong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meirong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"7","key":"5099_CR1","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913\u201328.","journal-title":"Gastroenterology"},{"issue":"1","key":"5099_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Ther. 2022;7(1):287.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"5099_CR3","first-page":"1175","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: Rev Jama. 2020;323(12):1175\u201383.","journal-title":"Nonalcoholic Steatohepatitis: Rev Jama"},{"key":"5099_CR4","doi-asserted-by":"crossref","unstructured":"Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview. Int J Mol Sci 2019, 20(8):1948.","DOI":"10.3390\/ijms20081948"},{"issue":"7","key":"5099_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"5099_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","volume":"97","author":"R Basu","year":"2022","unstructured":"Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: review of management for primary care providers. Mayo Clin Proc. 2022;97(9):1700\u201316.","journal-title":"Mayo Clin Proc"},{"issue":"27","key":"5099_CR7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","volume":"24","author":"YL Fang","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from two hit theory to multiple hit model. World J Gastroenterol. 2018;24(27):2974\u201383.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5099_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41418-020-00668-w","volume":"28","author":"L Tao","year":"2021","unstructured":"Tao L, Yi Y, Chen Y, Zhang H, Orning P, Lien E, Jie J, Zhang W, Xu Q, Li Y, et al. RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages. Cell Death Differ. 2021;28(4):1418\u201333.","journal-title":"Cell Death Differ"},{"issue":"6","key":"5099_CR9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jhep.2019.07.019","volume":"71","author":"Q Guo","year":"2019","unstructured":"Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, Kabashima A, Pavelko KD, Madden B, Alhuwaish H, et al. Integrin \u03b2(1)-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol. 2019;71(6):1193\u2013205.","journal-title":"J Hepatol"},{"issue":"8","key":"5099_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038\u201348.","journal-title":"Metabolism"},{"issue":"1","key":"5099_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","volume":"12","author":"J Dong","year":"2021","unstructured":"Dong J, Viswanathan S, Adami E, Singh BK, Chothani SP, Ng B, Lim WW, Zhou J, Tripathi M, Ko NSJ, et al. Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH. Nat Commun. 2021;12(1):66.","journal-title":"Nat Commun"},{"issue":"2","key":"5099_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280\u201395.","journal-title":"J Hepatol"},{"key":"5099_CR13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1038\/ncomms4017","volume":"4","author":"B Xiao","year":"2013","unstructured":"Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, Patel BR, Heath RB, Walker PA, Hallen S, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.","journal-title":"Nat Commun"},{"issue":"8","key":"5099_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-021-01510-4","volume":"81","author":"S Dehnavi","year":"2021","unstructured":"Dehnavi S, Kiani A, Sadeghi M, Biregani AF, Banach M, Atkin SL, Jamialahmadi T, Sahebkar A. Targeting AMPK by statins: A potential therapeutic approach. Drugs. 2021;81(8):923\u201333.","journal-title":"Drugs"},{"issue":"14","key":"5099_CR15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1128\/MCB.00244-16","volume":"36","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Tang T, Abbott M, Viscarra JA, Wang Y, Sul HS. AMPK phosphorylates desnutrin\/atgl and Hormone-Sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue. Mol Cell Biol. 2016;36(14):1961\u201376.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"5099_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","volume":"24","author":"GR Steinberg","year":"2023","unstructured":"Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24(4):255\u201372.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5099_CR17","doi-asserted-by":"crossref","unstructured":"Xu H, Lyu X, Guo X, Yang H, Duan L, Zhu H, Pan H, Gong F, Wang L. Distinct AMPK-Mediated FAS\/HSL pathway is implicated in the alleviating effect of Nuciferine on obesity and hepatic steatosis in HFD-Fed mice. Nutrients 2022, 14(9):1898.","DOI":"10.3390\/nu14091898"},{"key":"5099_CR18","doi-asserted-by":"publisher","first-page":"153739","DOI":"10.1016\/j.phymed.2021.153739","volume":"92","author":"R Huang","year":"2021","unstructured":"Huang R, Guo F, Li Y, Liang Y, Li G, Fu P, Ma L. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. Phytomedicine. 2021;92:153739.","journal-title":"Phytomedicine"},{"key":"5099_CR19","doi-asserted-by":"publisher","first-page":"175504","DOI":"10.1016\/j.ejphar.2023.175504","volume":"942","author":"Q Shen","year":"2023","unstructured":"Shen Q, Chen Y, Shi J, Pei C, Chen S, Huang S, Li W, Shi X, Liang J, Hou S. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. Eur J Pharmacol. 2023;942:175504.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5099_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/a-1970-3388","volume":"55","author":"D Lin","year":"2023","unstructured":"Lin D, Song Y. Dapagliflozin presented nonalcoholic fatty liver through metabolite extraction and AMPK\/NLRP3 signaling pathway. Horm Metab Res. 2023;55(1):75\u201384.","journal-title":"Horm Metab Res"},{"issue":"10","key":"5099_CR21","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1002\/ptr.7535","volume":"36","author":"Y Ding","year":"2022","unstructured":"Ding Y, Wang L, Liu B, Ren G, Okubo R, Yu J, Zhang C. Bryodulcosigenin attenuates bleomycin-induced pulmonary fibrosis via inhibiting AMPK-mediated mesenchymal epithelial transition and oxidative stress. Phytother Res. 2022;36(10):3911\u201323.","journal-title":"Phytother Res"},{"issue":"1","key":"5099_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13020-021-00469-4","volume":"16","author":"X Dai","year":"2021","unstructured":"Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med. 2021;16(1):68.","journal-title":"Chin Med"},{"key":"5099_CR23","doi-asserted-by":"publisher","first-page":"105849","DOI":"10.1016\/j.phrs.2021.105849","volume":"172","author":"M Chen","year":"2021","unstructured":"Chen M, Xie Y, Gong S, Wang Y, Yu H, Zhou T, Huang F, Guo X, Zhang H, Huang R, et al. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res. 2021;172:105849.","journal-title":"Pharmacol Res"},{"issue":"4","key":"5099_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jtcme.2023.02.010","volume":"13","author":"L Xu","year":"2023","unstructured":"Xu L, Cui H. Yinchenhao Tang alleviates high fat diet induced NAFLD by increasing NR1H4 and APOA1 expression. J Tradit Complement Med. 2023;13(4):325\u201336.","journal-title":"J Tradit Complement Med"},{"issue":"2","key":"5099_CR25","first-page":"253","volume":"40","author":"J Mu","year":"2020","unstructured":"Mu J, Cheng F, Wang Q, Wang X, Zhu W, Ma C, Yin X, Ren B, Lian Y, Du X, et al. Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B \/ pyrin domain-containing protein 3 pathway. J Tradit Chin Med. 2020;40(2):253\u201366.","journal-title":"J Tradit Chin Med"},{"key":"5099_CR26","doi-asserted-by":"crossref","unstructured":"Xing YF, Zhang Z, Fu WJ, Zhou DQ, Yuen AC, Mok DK, Chan CO, Tong GD. Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPAR\u03b1 and L-FABP Expressions in High-Fat-Fed Rats. Evid Based Complement Alternat Med 2016, 2016:7870189.","DOI":"10.1155\/2016\/7870189"},{"key":"5099_CR27","doi-asserted-by":"crossref","unstructured":"Yang H, Feng L, Xu L, Jiang D, Zhai F, Tong G, Xing Y. Intervention of Shugan Xiaozhi Decoction on Nonalcoholic Fatty Liver Disease via Mediating Gut-Liver Axis. Biomed Res Int 2022, 2022:4801695.","DOI":"10.1155\/2022\/4801695"},{"key":"5099_CR28","doi-asserted-by":"publisher","first-page":"e14171","DOI":"10.7717\/peerj.14171","volume":"10","author":"R Yang","year":"2022","unstructured":"Yang R, Yang H, Jiang D, Xu L, Feng L, Xing Y. Investigation of the potential mechanism of the Shugan Xiaozhi Decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular Docking and molecular dynamics simulation. PeerJ. 2022;10:e14171.","journal-title":"PeerJ"},{"issue":"07","key":"5099_CR29","first-page":"594","volume":"59","author":"H Tang","year":"2018","unstructured":"Tang H, Wei C, Zheng Y, Qiu M, Xing Y, Tong G. Evaluating the clinical effect of modified Shugan Xiaozhi Decoction intreating nonalcoholic fatly liver disease based on fibro scan technique. J Tradit Chin Med. 2018;59(07):594\u20138.","journal-title":"J Tradit Chin Med"},{"issue":"07","key":"5099_CR30","first-page":"17","volume":"45","author":"C Wei","year":"2013","unstructured":"Wei C, Tang H, Tong G. Clinical study of Shugan Xiaozhi formula combined with polyene phosphatidylcholine in the treatment of 36 cases of non-alcoholic steatohepatitis. J Jiangsu Tradit Chin Med. 2013;45(07):17\u20139.","journal-title":"J Jiangsu Tradit Chin Med"},{"issue":"15","key":"5099_CR31","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1021\/acs.jcim.3c00365","volume":"63","author":"X Liu","year":"2023","unstructured":"Liu X, Liu J, Fu B, Chen R, Jiang J, Chen H, Li R, Xing L, Yuan L, Chen X, et al. DCABM-TCM: A database of constituents absorbed into the blood and metabolites of traditional Chinese medicine. J Chem Inf Model. 2023;63(15):4948\u201359.","journal-title":"J Chem Inf Model"},{"issue":"11","key":"5099_CR32","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/jssc.202100906","volume":"45","author":"F Sun","year":"2022","unstructured":"Sun F, Zeng L, Li J, Zhong Y, Wu X, Wang K, Wang S, Liang S. Developing the liquid chromatography-mass spectrometry method for simultaneously quantifying five components in rat serums after oral administration of Hawthorn aqueous extracts and its application to a Pharmacokinetic study. J Sep Sci. 2022;45(11):1839\u201346.","journal-title":"J Sep Sci"},{"issue":"5","key":"5099_CR33","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","volume":"78","author":"E Lee","year":"2023","unstructured":"Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78(5):1048\u201362.","journal-title":"J Hepatol"},{"issue":"12","key":"5099_CR34","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1111\/febs.16015","volume":"288","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang QA, Liu Y, Jiang L. Energy metabolism in brown adipose tissue. Febs J. 2021;288(12):3647\u201362.","journal-title":"Febs J"},{"issue":"2","key":"5099_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","volume":"76","author":"F Foerster","year":"2022","unstructured":"Foerster F, Gairing SJ, M\u00fcller L, Galle PR. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76(2):446\u201357.","journal-title":"J Hepatol"},{"key":"5099_CR36","doi-asserted-by":"publisher","first-page":"154241","DOI":"10.1016\/j.phymed.2022.154241","volume":"104","author":"YF Deng","year":"2022","unstructured":"Deng YF, Xu QQ, Chen TQ, Ming JX, Wang YF, Mao LN, Zhou JJ, Sun WG, Zhou Q, Ren H, et al. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-\u03baB\/NLRP3 signaling pathway. Phytomedicine. 2022;104:154241.","journal-title":"Phytomedicine"},{"key":"5099_CR37","doi-asserted-by":"crossref","unstructured":"Liu M, Sun X, Chen B, Dai R, Xi Z, Xu H. Insights into manganese superoxide dismutase and human diseases. Int J Mol Sci 2022, 23(24) :15893.","DOI":"10.3390\/ijms232415893"},{"issue":"3","key":"5099_CR38","doi-asserted-by":"publisher","first-page":"e13622","DOI":"10.1111\/eci.13622","volume":"52","author":"A Karkucinska-Wieckowska","year":"2022","unstructured":"Karkucinska-Wieckowska A, Simoes ICM, Kalinowski P, Lebiedzinska-Arciszewska M, Zieniewicz K, Milkiewicz P, G\u00f3rska-Ponikowska M, Pinton P, Malik AN, Krawczyk M, et al. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. Eur J Clin Invest. 2022;52(3):e13622.","journal-title":"Eur J Clin Invest"},{"key":"5099_CR39","doi-asserted-by":"publisher","first-page":"110250","DOI":"10.1016\/j.cbi.2022.110250","volume":"368","author":"X Liu","year":"2022","unstructured":"Liu X, Hu M, Ye C, Liao L, Ding C, Sun L, Liang J, Chen Y. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK\/SREBP-1c\/PPAR\u03b1 pathway. Chem Biol Interact. 2022;368:110250.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"5099_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","volume":"29","author":"KC Lee","year":"2023","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29(1):77\u201398.","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl 1Suppl 1","key":"5099_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.13302","volume":"37","author":"AM Oseini","year":"2017","unstructured":"Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(Suppl 1Suppl 1):97\u2013103.","journal-title":"Liver Int"},{"issue":"3","key":"5099_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29(3):562\u201373.","journal-title":"Nat Med"},{"key":"5099_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fphar.2020.00351","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Xu Y, Guo W, Chen F, Zhang C, Tan HY, Wang N, Feng Y. The impacts of herbal medicines and natural products on regulating the hepatic lipid metabolism. Front Pharmacol. 2020;11:351.","journal-title":"Front Pharmacol"},{"key":"5099_CR44","doi-asserted-by":"publisher","first-page":"173976","DOI":"10.1016\/j.ejphar.2021.173976","volume":"898","author":"H Zhou","year":"2021","unstructured":"Zhou H, Ma C, Wang C, Gong L, Zhang Y, Li Y. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol. 2021;898:173976.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5099_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.diabres.2014.04.028","volume":"105","author":"YA Jung","year":"2014","unstructured":"Jung YA, Choi YK, Jung GS, Seo HY, Kim HS, Jang BK, Kim JG, Lee IK, Kim MK, Park KG. Sitagliptin attenuates methionine\/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract. 2014;105(1):47\u201357.","journal-title":"Diabetes Res Clin Pract"},{"key":"5099_CR46","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238.","journal-title":"Mol Metab"},{"key":"5099_CR47","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.coph.2022.102314","volume":"67","author":"B Wang","year":"2022","unstructured":"Wang B, Steinberg GR. Environmental toxicants, brown adipose tissue, and potential links to obesity and metabolic disease. Curr Opin Pharmacol. 2022;67:102314.","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"5099_CR48","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver cross talk in the control of Whole-Body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899\u2013912.","journal-title":"Gastroenterology"},{"key":"5099_CR49","doi-asserted-by":"crossref","unstructured":"Yang J, Zhang H, Parhat K, Xu H, Li M, Wang X, Ran C. Molecular imaging of brown adipose tissue mass. Int J Mol Sci 2021, 22(17):9436.","DOI":"10.3390\/ijms22179436"},{"key":"5099_CR50","doi-asserted-by":"publisher","first-page":"1001919","DOI":"10.3389\/fphar.2022.1001919","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Liu L, Zeng Y, Li D, Liu X, Hu C. Olanzapine induces weight gain in offspring of prenatally exposed Poly I:C rats by reducing brown fat thermogenic activity. Front Pharmacol. 2022;13:1001919.","journal-title":"Front Pharmacol"},{"issue":"6","key":"5099_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"5099_CR52","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136\u201360.","journal-title":"J Hepatol"},{"key":"5099_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","volume":"17","author":"M de Carvalho Ribeiro","year":"2022","unstructured":"de Carvalho Ribeiro M, Szabo G. Role of the inflammasome in liver disease. Annu Rev Pathol. 2022;17:345\u201365.","journal-title":"Annu Rev Pathol"},{"key":"5099_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41:301\u201316.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5099_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13020-022-00573-z","volume":"17","author":"J Zou","year":"2022","unstructured":"Zou J, Yan C, Wan JB. Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-\u03baB\/NLRP3 inflammasome-mediated hepatic inflammation in mice. Chin Med. 2022;17(1):17.","journal-title":"Chin Med"},{"issue":"3","key":"5099_CR56","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jcmgh.2021.12.002","volume":"13","author":"CH Hong","year":"2022","unstructured":"Hong CH, Ko MS, Kim JH, Cho H, Lee CH, Yoon JE, Yun JY, Baek IJ, Jang JE, Lee SE, et al. Sphingosine 1-Phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome. Cell Mol Gastroenterol Hepatol. 2022;13(3):925\u201347.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"5099_CR57","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jcmgh.2022.06.007","volume":"14","author":"B Kaufmann","year":"2022","unstructured":"Kaufmann B, Kui L, Reca A, Leszczynska A, Kim AD, Booshehri LM, Wree A, Friess H, Hartmann D, Broderick L, et al. Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in murine steatohepatitis. Cell Mol Gastroenterol Hepatol. 2022;14(4):751\u201367.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"5099_CR58","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","volume":"43","author":"RC Coll","year":"2022","unstructured":"Coll RC, Schroder K, Pelegr\u00edn P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653\u201368.","journal-title":"Trends Pharmacol Sci"},{"key":"5099_CR59","doi-asserted-by":"crossref","unstructured":"Ren GM, Li J, Zhang XC, Wang Y, Xiao Y, Zhang XY, Liu X, Zhang W, Ma WB, Zhang J et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. Sci Immunol 2021, 6(58):eabe2933.","DOI":"10.1126\/sciimmunol.abe2933"},{"issue":"5","key":"5099_CR60","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, et al. NLRP3 inflammasome Blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037\u201346.","journal-title":"J Hepatol"},{"key":"5099_CR61","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar S, Duan Q, Wu R, Harris EN, Su Q. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 2021;176:113869.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"5099_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hep4.1801","volume":"6","author":"CL Horn","year":"2022","unstructured":"Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of Cholesterol-Associated steatohepatitis in the development of NASH. Hepatol Commun. 2022;6(1):12\u201335.","journal-title":"Hepatol Commun"},{"issue":"2","key":"5099_CR63","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","volume":"52","author":"BA Neuschwander-Tetri","year":"2010","unstructured":"Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774\u201388.","journal-title":"Hepatology"},{"key":"5099_CR64","doi-asserted-by":"crossref","unstructured":"Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 2022, 12(6):824.","DOI":"10.3390\/biom12060824"},{"key":"5099_CR65","doi-asserted-by":"crossref","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci 2022, 23(24):15489.","DOI":"10.3390\/ijms232415489"},{"key":"5099_CR66","doi-asserted-by":"publisher","first-page":"153411","DOI":"10.1016\/j.phymed.2020.153411","volume":"81","author":"JY Lim","year":"2021","unstructured":"Lim JY, Lee JH, Yun DH, Lee YM, Kim DK. Inhibitory effects of Nodakenin on inflammation and cell death in lipopolysaccharide-induced liver injury mice. Phytomedicine. 2021;81:153411.","journal-title":"Phytomedicine"},{"key":"5099_CR67","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3389\/fphar.2019.01190","volume":"10","author":"Y Cui","year":"2019","unstructured":"Cui Y, Chang R, Zhang T, Zhou X, Wang Q, Gao H, Hou L, Loor JJ, Xu C. Chinese herbal formula (CHF03) attenuates Non-Alcoholic fatty liver disease (NAFLD) through inhibiting lipogenesis and Anti-Oxidation mechanisms. Front Pharmacol. 2019;10:1190.","journal-title":"Front Pharmacol"},{"key":"5099_CR68","doi-asserted-by":"crossref","unstructured":"Park JS, Rustamov N, Roh YS. The roles of NFR2-Regulated oxidative stress and mitochondrial quality control in chronic liver diseases. Antioxid (Basel) 2023, 12(11):1928.","DOI":"10.3390\/antiox12111928"},{"key":"5099_CR69","doi-asserted-by":"crossref","unstructured":"Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of oxidative stress in the pathogenesis of Non-Alcoholic fatty liver disease: implications for prevention and therapy. Antioxid (Basel) 2021, 10(2):174.","DOI":"10.3390\/antiox10020174"},{"key":"5099_CR70","doi-asserted-by":"crossref","unstructured":"Chen L, Hu SL, Xie J, Yan DY, Weng SJ, Tang JH, Wang BZ, Xie ZJ, Wu ZY, Yang L. Proanthocyanidins-Mediated Nrf2 Activation Ameliorates Glucocorticoid-Induced Oxidative Stress and Mitochondrial Dysfunction in Osteoblasts. Oxid Med Cell Longev 2020, 2020:9102012.","DOI":"10.1155\/2020\/9102012"},{"issue":"5","key":"5099_CR71","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.aohep.2019.11.010","volume":"19","author":"A Solano-Urrusquieta","year":"2020","unstructured":"Solano-Urrusquieta A, Morales-Gonz\u00e1lez JA, Castro-Narro GE, Cerda-Reyes E, Flores-Rangel PD, Fierros-Oceguera R. NRF-2 and nonalcoholic fatty liver disease. Ann Hepatol. 2020;19(5):458\u201365.","journal-title":"Ann Hepatol"},{"issue":"3","key":"5099_CR72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/clpt.2012.110","volume":"92","author":"AM Bataille","year":"2012","unstructured":"Bataille AM, Manautou JE. Nrf2: a potential target for new therapeutics in liver disease. Clin Pharmacol Ther. 2012;92(3):340\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"5099_CR73","doi-asserted-by":"publisher","first-page":"877924","DOI":"10.3389\/fphar.2022.877924","volume":"13","author":"Y Biao","year":"2022","unstructured":"Biao Y, Chen J, Liu C, Wang R, Han X, Li L, Zhang Y. Protective effect of Danshen Zexie Decoction against Non-Alcoholic fatty liver disease through Inhibition of ROS\/NLRP3\/IL-1\u03b2 pathway by Nrf2 signaling activation. Front Pharmacol. 2022;13:877924.","journal-title":"Front Pharmacol"},{"issue":"6","key":"5099_CR74","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1002\/hep.32068","volume":"74","author":"J Wan","year":"2021","unstructured":"Wan J, Zhang Y, Yang D, Liang Y, Yang L, Hu S, Liu Z, Fang Q, Tian S, Ding Y. Gastrodin improves nonalcoholic fatty liver disease through activation of the adenosine Monophosphate-Activated protein kinase signaling pathway. Hepatology. 2021;74(6):3074\u201390.","journal-title":"Hepatology"},{"key":"5099_CR75","doi-asserted-by":"publisher","first-page":"970292","DOI":"10.3389\/fphys.2022.970292","volume":"13","author":"C Fang","year":"2022","unstructured":"Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, Han D. The AMPK pathway in fatty liver disease. Front Physiol. 2022;13:970292.","journal-title":"Front Physiol"},{"issue":"1","key":"5099_CR76","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41467-019-08585-4","volume":"10","author":"Y Han","year":"2019","unstructured":"Han Y, Hu Z, Cui A, Liu Z, Ma F, Xue Y, Liu Y, Zhang F, Zhao Z, Yu Y, et al. Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nat Commun. 2019;10(1):623.","journal-title":"Nat Commun"},{"issue":"Pt 1","key":"5099_CR77","doi-asserted-by":"publisher","first-page":"117162","DOI":"10.1016\/j.jep.2023.117162","volume":"319","author":"Y Guo","year":"2024","unstructured":"Guo Y, Sun Q, Wang S, Zhang M, Lei Y, Wu J, Wang X, Hu W, Meng H, Li Z, et al. Corydalis saxicola bunting total alkaloids improve NAFLD by suppressing de Novo lipogenesis through the AMPK-SREBP1 axis. J Ethnopharmacol. 2024;319(Pt 1):117162.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"5099_CR78","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4254\/wjh.v6.i8.570","volume":"6","author":"VG Giby","year":"2014","unstructured":"Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(8):570\u20139.","journal-title":"World J Hepatol"},{"issue":"9","key":"5099_CR79","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. 2020;11(9):802.","journal-title":"Cell Death Dis"},{"key":"5099_CR80","doi-asserted-by":"publisher","first-page":"154589","DOI":"10.1016\/j.phymed.2022.154589","volume":"109","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang W, Yang L, Zhao W, Liu Z, Wang E, Wang J. Phytochemical Gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. Phytomedicine. 2023;109:154589.","journal-title":"Phytomedicine"},{"issue":"2","key":"5099_CR81","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbrc.2017.06.076","volume":"490","author":"C Zhao","year":"2017","unstructured":"Zhao C, Zhang Y, Liu H, Li P, Zhang H, Cheng G. Fortunellin protects against high fructose-induced diabetic heart injury in mice by suppressing inflammation and oxidative stress via AMPK\/Nrf-2 pathway regulation. Biochem Biophys Res Commun. 2017;490(2):552\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"5099_CR82","doi-asserted-by":"publisher","first-page":"974825","DOI":"10.3389\/fphys.2022.974825","volume":"13","author":"Y Yao","year":"2022","unstructured":"Yao Y, Li L, Wang H, Yang Y, Ma H. Activated AMP-activated protein kinase prevents hepatic steatosis, oxidative stress and inflammation in primary chicken hepatocytes. Front Physiol. 2022;13:974825.","journal-title":"Front Physiol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05099-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:05:51Z","timestamp":1762884351000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-05099-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5099"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05099-z","relation":{},"ISSN":["2662-7671"],"issn-type":[{"type":"electronic","value":"2662-7671"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was reviewed and approved by the Experimental Animal Center of Shenzhen institute for drug control. The study was conducted in accordance with the local legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}